Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986419 Safety and Thorough QT Study
NCT06846866Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986419 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants with Non-serious Adverse Events (Part 1) at 42 days, Number of Participants with Serious Adverse Events (Part 1) at 42 days and 8 more. Started Feb 2025; status: completed.
02
Drugs
BMS-986419
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06846866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846866.